94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1599100
This article is part of the Research TopicExploring key pathways in the progression of gastrointestinal diseases based on metabolic reprogramming and developing drugs targeting metabolismView all articles
Mechanism of Action and Therapeutic Value of Anoctamin-1 in Gastrointestinal Cancers
Provisionally accepted- The First hospital of Hebei Medical University, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Gastrointestinal (GI) cancers are main causes of poor health, with most remaining difficult to treat effectively. Identifying new targets for treatment is crucial for improving the efficacy of tumour therapies and enhancing patient quality of life. Anoctamin-1 (ANO1), a crucial component of calcium-activated chloride channels (CaCCs), is expressed widely in various cell types, including epithelial cells, vascular smooth muscle cells, and tumour cells, and influences cell proliferation and migration. Nonetheless, the exact pathways through which ANO1 contributes to malignant transformation and immune responses remain elusive. This review comprehensively examines the regulatory functions and potential therapeutic applications of ANO1 in GI cancers. The goal of this work is to offer new perspectives for further study on the role of ANO1 in gastrointestinal cancers and to support improvements in therapeutic strategies for cancer diagnosis and treatment through the targeting of ANO1.
Keywords: anoctamin-1, gastrointestinal cancers, mechanism, therapy, prognosis ANO1, anoctamin-1, TMEM16A, transmembrane protein 16A, DOG1, discovered on gastrointestinal stromal tumour 1, GI, gastrointestinal, CaCCs, calcium-activated chloride channels, STAT6, signal transducer and activator of transcription 6, CRC, colorectal cancer, HCC, hepatocellular carcinoma
Received: 24 Mar 2025; Accepted: 14 Apr 2025.
Copyright: © 2025 Zhang, Lin, Xu, Zhou, Mu, Shi and Lv. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ruizhe Shi, The First hospital of Hebei Medical University, Shijiazhuang, China
Yalei Lv, The First hospital of Hebei Medical University, Shijiazhuang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.